A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors

Brief description of study

This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it helps patients with different types of cancer, like ovarian, endometrial, cervical, lung, breast, pancreatic, and colorectal cancers. The study has two phases. In Phase 1a, doctors will find the best dose of LY4170156 by giving it to patients and checking for side effects and how well it works. If needed, they will try different doses to see which one is the safest and most effective. In Phase 1b, the best dose from Phase 1a will be given to more patients to see how well it works as a single treatment. Patients will be divided into groups based on the type of cancer and a specific antigen in their tumors to which the ADC binds, which will be tested in a lab. The study will make sure that the drug is given at the right dose and checks how patients feel during the treatment.


Clinical Study Identifier: s23-01602
ClinicalTrials.gov Identifier: NCT06400472
Principal Investigator: Bhavana Pothuri.
Other Investigators: Anam Qureshi, Kent Chan, Cindy Corbo, Nitish Mehta, Deanna Gerber, Olivia Richardson Khouri, Laura Palazzolo, Marina Stasenko, Jonathan B Kahn, Fabia Brisard Pierrot, Kathleen M Lutz, Leslie R Boyd, Christina Grace Wilson, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Carol M Lee, Whitfield B. Growdon, Victoria Helen Dowd, Edward A Jimenez, Erin Annette Reese, Kelly A Levine, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.